Industry News

• Gilead and Carna Bio announce R&D collaboration to develop immuno-oncology therapies  Gilead Sciences and Carna Biosciences announced the companies have entered into a research and development collaboration to develop and commercialize small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform.
  June 24, 2019  
• Mirati Therapeutics announces proposed public offering of common stock  Mirati Therapeutics announced it has commenced an underwritten public offering of shares of its common stock. Mirati expects to grant the underwriters of the offering a 30-day option to purchase additional shares of its common stock at the public offering price.
  June 24, 2019  
• Conatus to explore strategic alternatives and implement restructuring plan  Conatus announced it has engaged Oppenheimer & Co. as its financial advisor to assist in the exploration and evaluation of strategic alternatives to enhance shareholder value. Conatus is implementing a restructuring plan that includes reducing staff by 40% and suspending development of CTS-2090.
  June 24, 2019  
• ArQule announces commencement of proposed public offering of common stock  ArQule announced it has commenced an underwritten public offering to issue and sell shares of its common stock. ArQule expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.
  June 24, 2019  
• Apollo Endosurgery announces completion of patient enrollment for multi-center ESG trial  Apollo Endosurgery announced the final patient has been enrolled in the Multi-Center ESG Randomized Interventional Trial (MERIT). The US based, prospective randomized multi-center-controlled trial is evaluating the effectiveness of the endoscopic sleeve gastroplasty procedure.
  June 24, 2019  
• New ProActiveTM study from Natera will test for rejection in 3,000 kidney transplants  Natera announced a nationwide registry study for kidney transplant recipients called ProActive. This is one of the largest known prospective studies to date, incorporating donor-derived cell-free DNA testing into medical management of organ transplant recipients.
  June 24, 2019  
• Bayer and AlphaBio Control sign distribution agreement for biological pest control product  Bayer and AlphaBio Control have signed a distribution agreement to market Flipper™, an innovative biological pest control product developed by AlphaBio. Under the terms, AlphaBio grants Bayer worldwide exclusive right (except France) to commercialize Flipper for agriculture and non-ag uses.
  June 24, 2019  
• Nutrition is the missing ingredient in home health today, new study shows  New research from Advocate Health Care and Abbott found that prioritizing nutrition care for home health patients at risk for malnutrition had a dramatic impact on helping keep them out of the hospital - resulting in millions of dollars in healthcare cost savings.
  June 24, 2019  
• NantKwest launches phase I clinical trial with targeted PD-L1 t-haNK cell therapy  NantKwest announced the company’s PD-L1 t-haNK investigational new drug application has cleared FDA review and the program has now transitioned to a first-in-human clinical trial in patients with locally advanced or metastatic solid cancers.
  June 24, 2019  
• Minerva Neurosciences announces achievement of primary and key secondary objectives   Minerva Neurosciences announced results of a clinical trial (ISM2005) of seltorexant (MIN-202) in patients with insomnia disorder that demonstrated highly statistically significant and clinically meaningful improvement on LPS at Night 1, the primary endpoint of the study.
  June 24, 2019  

   (next 10 articles)